{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:44:21Z","timestamp":1792115061410,"version":"4.4.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jaci.2026.05.004","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T06:17:21Z","timestamp":1778739441000},"page":"872-882.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["CXCL16 as a potential therapeutic target to limit the activity of asthmatic CD4 memory T cells"],"prefix":"10.1016","volume":"158","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9432-5716","authenticated-orcid":false,"given":"Gurupreet S.","family":"Sethi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6062-3635","authenticated-orcid":false,"given":"Michael","family":"Croft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2026.05.004_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109902","article-title":"Arthritis flares mediated by tissue-resident memory T cells in the joint","volume":"37","author":"Chang","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.jaci.2026.05.004_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.crimmu.2023.100067","article-title":"Characteristics and sources of tissue-resident memory T cells in psoriasis relapse","volume":"4","author":"Dong","year":"2023","journal-title":"Curr Res Immunol"},{"key":"10.1016\/j.jaci.2026.05.004_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.951361","article-title":"Contribution of circulatory cells to asthma exacerbations and lung tissue-resident CD4 T cell memory","volume":"13","author":"Sethi","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2026.05.004_bib4","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1016\/j.celrep.2017.08.078","article-title":"Human tissue-resident memory T cells are defined by core transcriptional and functional signatures in lymphoid and mucosal sites","volume":"20","author":"Kumar","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.jaci.2026.05.004_bib5","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1111\/febs.14466","article-title":"A guide to chemokines and their receptors","volume":"285","author":"Hughes","year":"2018","journal-title":"FEBS J"},{"key":"10.1016\/j.jaci.2026.05.004_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003329","article-title":"CXCR6 by increasing retention of memory CD8+ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer","volume":"9","author":"Muthuswamy","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaci.2026.05.004_bib7","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1084\/jem.20181308","article-title":"CXCR6 regulates localization of tissue-resident memory CD8 T cells to the airways","volume":"216","author":"Wein","year":"2019","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2026.05.004_bib8","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/infdis\/jiu281","article-title":"The chemokine receptor CXCR6 is required for the maintenance of liver memory CD8+ T cells specific for infectious pathogens","volume":"210","author":"Tse","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaci.2026.05.004_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/jimmun\/vkaf219","article-title":"CXCR6 promotes dermal CD8+ T cell survival and transition to long-term tissue residence","volume":"215","author":"Heim","year":"2026","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2026.05.004_bib10","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/79738","article-title":"A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo","volume":"1","author":"Matloubian","year":"2000","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2026.05.004_bib11","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/sj.jid.5700751","article-title":"Constitutive expression and regulated release of the transmembrane chemokine CXCL16 in human and murine skin","volume":"127","author":"Scholz","year":"2007","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2026.05.004_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110530","article-title":"Role of the CXCR6\/CXCL16 axis in autoimmune diseases","volume":"121","author":"Bao","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaci.2026.05.004_bib13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41423-018-0182-0","article-title":"Kinetics of the accumulation of group 2 innate lymphoid cells in IL-33\u2013induced and IL-25\u2013induced murine models of asthma: a potential role for the chemokine CXCL16","volume":"16","author":"Li","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jaci.2026.05.004_bib14","first-page":"90","article-title":"CXCL16 knockout inhibit asthma airway inflammation by suppressing H2-DM molecular mediated antigen presentation","volume":"11","author":"Liu","year":"2025","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.jaci.2026.05.004_bib15","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1126\/science.1219328","article-title":"Microbial exposure during early life has persistent effects on natural killer T cell function","volume":"336","author":"Olszak","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.jaci.2026.05.004_bib16","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.jaci.2024.12.1097","article-title":"ICOSL, OX40L, and CD30L control persistence of asthmatic CD4 tissue-resident memory CD4 T cells","volume":"155","author":"Sethi","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.05.004_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abq6352","article-title":"A human model of asthma exacerbation reveals transcriptional programs and cell circuits specific to allergic asthma","volume":"8","author":"Alladina","year":"2023","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaci.2026.05.004_bib18","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1111\/all.15722","article-title":"Anti-CD3 inhibits circulatory and tissue-resident memory CD4 T cells that drive asthma exacerbations in mice","volume":"78","author":"Sethi","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.05.004_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2024.102510","article-title":"Chemokines that govern T cell activity in tumors","volume":"92","author":"Mempel","year":"2025","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaci.2026.05.004_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.817473","article-title":"Chemokine-driven migration of pro-inflammatory CD4+ T cells in CNS autoimmune disease","volume":"13","author":"Heng","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2026.05.004_bib21","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1002\/art.21975","article-title":"A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis","volume":"54","author":"Haringman","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2026.05.004_bib22","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/art.23591","article-title":"Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial","volume":"58","author":"Vergunst","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2026.05.004_bib23","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1136\/ard.2010.131235","article-title":"CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial","volume":"69","author":"van Kuijk","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2026.05.004_bib24","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1002\/art.27652","article-title":"Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate","volume":"62","author":"Gerlag","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2026.05.004_bib25","doi-asserted-by":"crossref","DOI":"10.1186\/ar3685","article-title":"Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial","volume":"14","author":"Fleishaker","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaci.2026.05.004_bib26","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1002\/art.24978","article-title":"MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study","volume":"60","author":"Vergunst","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2026.05.004_bib27","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.2174\/156802610791561237","article-title":"CCR1 antagonists: what have we learned from clinical trials","volume":"10","author":"Gladue","year":"2010","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.jaci.2026.05.004_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.812431","article-title":"Functional roles of chemokine receptor CCR2 and its ligands in liver disease","volume":"13","author":"She","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2026.05.004_bib29","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1182\/blood.2020007197","article-title":"Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome","volume":"136","author":"Dale","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.05.004_bib30","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1182\/blood-2011-10-383406","article-title":"A phase 1\/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia","volume":"119","author":"Uy","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.05.004_bib31","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","article-title":"BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial","volume":"26","author":"Bockorny","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2026.05.004_bib32","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S1470-2045(18)30147-5","article-title":"Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial","volume":"19","author":"Pernas","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaci.2026.05.004_bib33","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jaci.2023.02.028","article-title":"CCL5 is a potential bridge between type 1 and type 2 inflammation in asthma","volume":"152","author":"Gauthier","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.05.004_bib34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jaci.2021.05.044","article-title":"Dual role for CXCR3 and CCR5 in asthmatic type 1 inflammation","volume":"149","author":"Gauthier","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.05.004_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.951361","article-title":"Contribution of circulatory cells to asthma exacerbations and lung tissue-resident CD4 T cell memory","volume":"13","author":"Sethi","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2026.05.004_bib36","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.jaci.2024.12.1097","article-title":"ICOSL, OX40L, and CD30L control persistence of asthmatic CD4 tissue-resident memory CD4 T cells","volume":"155","author":"Sethi","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.05.004_bib37","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1111\/all.15722","article-title":"Anti-CD3 inhibits circulatory and tissue-resident memory CD4 T cells that drive asthma exacerbations in mice","volume":"78","author":"Sethi","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.05.004_bib38","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1016\/j.jaci.2020.10.037","article-title":"Combination blockade of OX40L and CD30L inhibits allergen-driven memory TH2 cell reactivity and lung inflammation","volume":"147","author":"Gracias","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.05.004_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abq6352","article-title":"A human model of asthma exacerbation reveals transcriptional programs and cell circuits specific to allergic asthma","volume":"8","author":"Alladina","year":"2023","journal-title":"Sci Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926003404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926003404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:49:09Z","timestamp":1792111749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674926003404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0091674926003404"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2026.05.004","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CXCL16 as a potential therapeutic target to limit the activity of asthmatic CD4 memory T cells","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2026.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}